Ajanta Pharma, a company engaged in manufacturing & marketing of pharmaceutical products, announced a substantial rise in consolidated net profit for the quarter ended March 2016. During the quarter, the profit of the company rose 43.39% to Rs 1,063.10 million from Rs 741.40 million in the same quarter previous year.

Revenues for the quarter rose 14.42% to Rs 4,257.30 million, compared with Rs 3,721 million for the prior year period.

Operating margin for the quarter stood at 33.00 percent as compared to 35.77 percent for the previous year period. Operating Income for the quarter was Rs 1,405.10 million, compared with Rs 1330.9 million in the previous year period.

Earnings per share for the quarter stood at Rs 12.08, registering 43.47% growth over previous year period.

Yogesh Agrawal, managing director said, ''Despite challenges of foreign currency volatility and scarcity in the emerging markets, we have posted overall satisfactory growth during the quarter. We have enhanced our focus on the R&D which reflects in our spend levels. Our capex plans are on-course to complete on the target dates.''

For Q4 FY 2016, India branded business (excluding institution) was Rs 1.13 billion posting healthy growth of 16%. Total India revenue (including Institution) was Rs 1.19 billion, up 5% over Q4 FY 2015.

Shares of the company declined Rs 53.3, or 3.47%, to trade at Rs 1,482.00. The total volume of shares traded was 62,992 at the BSE (1.47 p.m., Friday).